​

Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

ASND Stock Forecast

Ascendis Pharma (ASND) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $307.85, with a high of $344.00 and a low of $268.00. This represents a 25.58% increase from the last price of $245.15.

$200 $230 $260 $290 $320 $350 High: $344 Avg: $307.85 Low: $268 Last Closed Price: $245.15

ASND Stock Rating

Ascendis Pharma stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (92.31%), 2 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 2 24 0 Strong Sell Sell Hold Buy Strong Buy

ASND Price Target Upside V Benchmarks

TypeNameUpside
StockAscendis Pharma25.58%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts21535
Avg Price Target$268.50$314.27$303.37
Last Closing Price$245.15$245.15$245.15
Upside/Downside9.52%28.19%23.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26515---20
Sep, 26416---20
Aug, 26414---18
Jul, 26414---18
Jun, 26413---17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 26, 2026Canaccord Genuity$268.00$243.3710.12%9.32%
Oct 15, 2026UBS$269.00$227.0018.50%9.73%
Sep 16, 2026UBS$344.00$239.7743.47%40.32%
Sep 15, 2026Martin AusterRaymond James$287.00$264.928.33%17.07%
Sep 10, 2026H.C. Wainwright$344.00$260.8131.90%40.32%
Sep 01, 2026Leland GershellOppenheimer$312.00$260.2519.88%27.27%
Sep 01, 2026Maxwell SkorMorgan Stanley$273.00$263.043.79%11.36%
Aug 31, 2026Jefferies$330.00$265.2624.41%34.61%
Aug 31, 2026Stifel Nicolaus$326.00$265.3222.87%32.98%
Aug 31, 2026UBS$345.00$247.9139.16%40.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 26, 2026CitigroupBuyBuyhold
Sep 16, 2026UBSBuyBuyhold
Sep 15, 2026Raymond JamesOutperformdowngrade
Sep 10, 2026Cowen & Co.BuyBuyhold
Sep 10, 2026BMO CapitalOutperformOutperformhold
Sep 01, 2026OppenheimerOutperformOutperformhold
Sep 01, 2026Morgan StanleyOverweightOverweighthold
Sep 01, 2026Bank of America SecuritiesBuyBuyhold
Aug 31, 2026H.C. WainwrightBuyBuyhold
Aug 27, 2026H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.00$-10.40$-8.55-----
Avg Forecast$-7.41$-9.55$-8.86$-6.98$-3.90$1.06$10.04$13.91
High Forecast$-6.04$-7.77$-7.55$-5.72$-1.46$5.22$26.67$21.09
Low Forecast$-10.50$-14.59$-10.95$-7.73$-6.36$-0.88$3.69$10.79
Surprise %-5.53%8.90%-3.50%-----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.78M$51.17M$266.72M-----
Avg Forecast$6.60M$45.90M$224.61M$300.07M$530.08M$1.00B$1.73B$2.32B
High Forecast$8.71M$64.54M$279.10M$365.49M$749.98M$1.01B$2.41B$3.24B
Low Forecast$5.66M$39.31M$194.11M$258.44M$448.72M$996.14M$1.43B$1.92B
Surprise %17.89%11.49%18.75%-----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-383.58M$-583.19M$-481.45M-----
Avg Forecast$-417.32M$-537.67M$-437.49M$-381.83M$-196.74M$137.26M$538.04M$782.81M
High Forecast$-340.10M$-437.37M$-425.03M$-322.10M$-82.43M$293.94M$1.50B$1.19B
Low Forecast$-590.82M$-821.49M$-616.22M$-435.36M$-357.87M$-49.59M$207.64M$607.46M
Surprise %-8.08%8.47%10.05%-----

ASND Forecast FAQ

Is Ascendis Pharma stock a buy?

Ascendis Pharma stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ascendis Pharma is a favorable investment for most analysts.

What is Ascendis Pharma's price target?

Ascendis Pharma's price target, set by 26 Wall Street analysts, averages $307.85 over the next 12 months. The price target range spans from $268 at the low end to $344 at the high end, suggesting a potential 25.58% change from the previous closing price of $245.15.

How does Ascendis Pharma stock forecast compare to its benchmarks?

Ascendis Pharma's stock forecast shows a 25.58% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ascendis Pharma over the past three months?

  • October 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ascendis Pharma’s EPS forecast?

Ascendis Pharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-6.98, marking a -18.36% decrease from the reported $-8.55 in 2023. Estimates for the following years are $-3.9 in 2025, $1.06 in 2026, $10.04 in 2027, and $13.91 in 2028.

What is Ascendis Pharma’s revenue forecast?

Ascendis Pharma's average annual revenue forecast for its fiscal year ending in December 2024 is $300.07M, reflecting a 12.50% increase from the reported $266.72M in 2023. The forecast for 2025 is $530.08M, followed by $1B for 2026, $1.73B for 2027, and $2.32B for 2028.

What is Ascendis Pharma’s net income forecast?

Ascendis Pharma's net income forecast for the fiscal year ending in December 2024 stands at $-382M, representing a -20.69% decrease from the reported $-481M in 2023. Projections indicate $-197M in 2025, $137.26M in 2026, $538.04M in 2027, and $782.81M in 2028.